Eli Lilly and Company
LLY
$734.57
-$16.88-2.25%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 80.93% | 102.08% | 67.79% | 13.00% | 7.94% |
| Total Depreciation and Amortization | 16.81% | 15.67% | 10.23% | 10.04% | 8.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 258.92% | 250.08% | 455.31% | 194.23% | 274.34% |
| Change in Net Operating Assets | -40.80% | -76.27% | -795.66% | -865.46% | -2,615.33% |
| Cash from Operations | 153.50% | 107.96% | -2.94% | -27.75% | -45.90% |
| Capital Expenditure | -48.22% | -46.70% | -60.98% | -68.42% | -74.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 9.25% | 9.25% | -508.80% | -508.80% | -219.16% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -74.71% | -23.87% | -87.13% | -1,509.59% | -204.66% |
| Cash from Investing | -50.18% | -30.04% | -99.26% | -207.91% | -123.82% |
| Total Debt Issued | 2.53% | 31.99% | 320.01% | 233.72% | 124.82% |
| Total Debt Repaid | 122.66% | -- | -- | 35.19% | -57.88% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -233.33% | 40.52% | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.07% | -15.02% | -15.11% | -15.11% | -15.10% |
| Other Financing Activities | -77.35% | -46.45% | -50.33% | -38.26% | -44.33% |
| Cash from Financing | 5.38% | -64.81% | 520.01% | 277.17% | 231.00% |
| Foreign Exchange rate Adjustments | -219.39% | -275.98% | 393.70% | 140.39% | 161.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 158.31% | -40.15% | 517.67% | 638.97% | -199.91% |